Agilent Awards Microarray Prize to Dutch Scientist for Research on Tumor Suppressor Genes
News May 01, 2007
Agilent Technologies Inc. has announced that Klaas Kok, Ph.D., of the Department of Genetics, University Medical Center Groningen in the Netherlands, has won 50 free microarrays in the Agilent Technologies Microarray Contest on the basis of his innovative research.
Dr. Kok’s winning entry combines array-based comparative genomic hybridization (aCGH) with traditional gene-expression profiling in the search for tumor suppressor (TS) genes implicated in conventional renal cell carcinoma (cRCC). Nearly 100 teams entered the contest, which ran from November 2006 through January 2007.
The winner had a choice of two prizes: 50 244K microarrays or 35 slides, each containing four 44K microarrays, including catalog or custom content. Dr. Kok selected the four-array-per-slide format to do high-resolution aCGH experiments to identify regions of copy number loss and cRCC-related candidate TS genes.
“Agilent is an excellent platform for performing high-resolution array CGH, and is thus, by far, the most ideal platform for integrating expression data with array CGH data,” said Kok.
“We congratulate Dr. Kok and are pleased to be supporting his research, which could have broad implications across many cancers involving tumor suppressor mechanisms,” said Linda Roettger, marketing manager, Agilent Life Sciences Solutions Unit.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.